Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ebalzotan SCHEMBL247755 | 1.00 | DRD2 (0.77) | DRD2 | |
| Hydrochloric Acid SCHEMBL8823814 | 0.90 | DRD2 (0.77) | DRD2 | |
| Hydrochloric Acid SCHEMBL8823793 | 0.89 | DRD2 (0.76) | DRD2 | |
| SCHEMBL9568770 | 0.89 | DRD2 (0.76) | DRD2 | |
| SCHEMBL8823678 | 0.88 | DRD2 (0.78) | DRD2 | |
| SCHEMBL8823628 | 0.88 | DRD2 (0.78) | DRD2 | |
| SCHEMBL8823789 | 0.87 | DRD2 (0.76) | DRD2 | |
| SCHEMBL8823704 | 0.87 | DRD2 (0.58) | DRD2 | |
| SCHEMBL8823697 | 0.87 | DRD2 (0.58) | DRD2 | |
| SCHEMBL8823639 | 0.86 | DRD2 (0.82) | DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5656658-A | Method for the treatment of anxiety | ASTRA AKTIEBOLAG (SE) | 1997-08-12 | — | — | US | claimed |
| US-5641807-A | Method for the treatment of depression | ASTRA AKTIEBOLAG (SE) | 1997-06-24 | — | — | US | claimed |
| US-5639784-A | ADMINISTERING 3-AMINO-5-CARBAMOYL-CHROMENES AND DERIVATIVES | ASTRA AKTIEBOLAG (SE) | 1997-06-17 | — | — | US | claimed |
| EP-0607274-B1 | 3-(N-ISOPROPYL-N-n-PROPYLAMINO)-5-(N-ISOPROPYL)CARBAMOYLCHROMAN | ASTRA AB (SE) | 1996-06-26 | — | — | EP | claimed |
| US-5420151-A | Chroman derivatives | AKTIEBOLAGET ASTRA (SE) | 1995-05-30 | — | — | US | claimed |
| EP-0538222-A1 | 3-(N-Isopropyl-N-n-propylamino)-5-(N-isopropyl)carbamoylchroman as a selective 5-hydroxytryptamine receptor stimulant | Astra Aktiebolag (SE) | 1993-04-21 | — | — | EP | claimed |
| US-20050004105-A1 | Treatment for a attention-deficit hyperactivity disorder | PSYCHOGENCIS, INC. | 2005-01-06 | — | — | US | disclosed |
| WO-2004069339-A1 | TREATMENT FOR ATTENTION-DEFICIT HYPERACTIVITY DISORDER | PSYCHOGENICS INC. (US) | 2004-08-19 | — | — | WO | disclosed |
| US-5656657-A | Chroman derivatives | ASTRA AKTIEBOLAG (SE) | 1997-08-12 | — | — | US | disclosed |
| US-5656658-A | Method for the treatment of anxiety | ASTRA AKTIEBOLAG (SE) | 1997-08-12 | — | — | US | disclosed |
| US-5650524-A | Process for preparing (R)-3-amino-5-methoxychroman | ASTRA AKTIEBOLAG (SE) | 1997-07-22 | — | — | US | disclosed |
| US-5646309-A | Intermediates in the synthesis of chroman derivatives | ASTRA AKTIEBOLAG (SE) | 1997-07-08 | — | — | US | disclosed |
| US-5641807-A | Method for the treatment of depression | ASTRA AKTIEBOLAG (SE) | 1997-06-24 | — | — | US | disclosed |
| EP-0607274-A1 | 3-(N-ISOPROPYL-N-n-PROPYLAMINO)-5-(N-ISOPROPYL)CARBAMOYLCHROMAN. | ASTRA AB (SE) | 1994-07-27 | — | — | EP | disclosed |
| EP-0538222-A1 | 3-(N-Isopropyl-N-n-propylamino)-5-(N-isopropyl)carbamoylchroman as a selective 5-hydroxytryptamine receptor stimulant | Astra Aktiebolag (SE) | 1993-04-21 | — | — | EP | disclosed |
| EP-0538222-A1 | 3-(N-Isopropyl-N-n-propylamino)-5-(N-isopropyl)carbamoylchroman as a selective 5-hydroxytryptamine receptor stimulant | Astra Aktiebolag (SE) | 1993-04-21 | — | — | EP | disclosed |
| EP-0538222-A1 | 3-(N-Isopropyl-N-n-propylamino)-5-(N-isopropyl)carbamoylchroman as a selective 5-hydroxytryptamine receptor stimulant | Astra Aktiebolag (SE) | 1993-04-21 | — | — | EP | disclosed |
| WO-1993007135-A1 | 3-(N-ISOPROPYL-N-N-PROPYLAMINO)-5-(N-ISOPROPYL)CARBAMOYLCHROMAN | AKTIEBOLAGET ASTRA (SE) | 1993-04-15 | — | — | WO | disclosed |
| WO-1993007135-A1 | 3-(N-ISOPROPYL-N-N-PROPYLAMINO)-5-(N-ISOPROPYL)CARBAMOYLCHROMAN | AKTIEBOLAGET ASTRA (SE) | 1993-04-15 | — | — | WO | disclosed |
| WO-1993007135-A1 | 3-(N-ISOPROPYL-N-N-PROPYLAMINO)-5-(N-ISOPROPYL)CARBAMOYLCHROMAN | AKTIEBOLAGET ASTRA (SE) | 1993-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004105-A1 | Treatment for a attention-deficit hyperactivity disorder | HTR1A, HTR5A, HTR2A | DRD2 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.